Blockchain Registration Transaction Record

Vitamin B3 Shows Promise in Fighting Aggressive Brain Cancer

University of Calgary researchers explore vitamin B3 (niacin) for glioblastoma treatment, with early studies showing restored immune function. Learn about ongoing trials and CNS Pharmaceuticals' role.

This news matters because glioblastoma is a devastating disease with limited treatment options and poor survival rates, often affecting individuals in their prime. If vitamin B3 proves effective in clinical trials, it could lead to more accessible and affordable combination therapies, potentially improving patient outcomes and quality of life. The involvement of companies like CNS Pharmaceuticals Inc. signals growing investment in brain cancer research, which may accelerate innovation and bring new hope to patients and families facing this diagnosis. Ultimately, this research highlights the potential of repurposing common vitamins to combat complex cancers, underscoring the importance of continued scientific exploration in oncology.